Peter Heerma
Chief Commercial Officer
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Travere Therapeutics, Inc. (TVTX) | Chief Commercial Officer | $527,917 | $2,261,751 |
| 2024 | Travere Therapeutics, Inc. (TVTX) | Chief Commercial Officer | $503,750 | $1,513,360 |
| 2023 | Travere Therapeutics, Inc. (TVTX) | Chief Commercial Officer | $487,167 | $2,003,914 |
| 2022 | Travere Therapeutics, Inc. (TVTX) | Chief Commercial Officer | $453,190 | $2,005,747 |
| 2021 | Travere Therapeutics, Inc. (TVTX) | Chief Commercial Officer | $421,685 | $1,880,976 |
| 2020 | Travere Therapeutics, Inc. (TVTX) | Chief Commercial Officer | $407,667 | $1,532,290 |
| 2019 | Travere Therapeutics, Inc. (TVTX) | Chief Commercial Officer | $100,000 | $1,325,278 |
Earnings-call appearances
-
Travere Therapeutics FDA Approval of FILSPARI in FSGS Conference Call2026-04-13
Travere Therapeutics, Inc. (TVTX)
-
Travere Therapeutics, Inc. Q4 FY2025 Earnings Call2026-02-19
Travere Therapeutics, Inc. (TVTX)
-
Travere Therapeutics, Inc. Q3 FY2025 Earnings Call2025-10-30
Travere Therapeutics, Inc. (TVTX)
-
Travere Therapeutics, Inc. Q2 FY2025 Earnings Call2025-08-06
Travere Therapeutics, Inc. (TVTX)
-
Travere Therapeutics, Inc. Q1 FY2025 Earnings Call2025-05-01
Travere Therapeutics, Inc. (TVTX)
-
Travere Therapeutics, Inc. Q4 FY2024 Earnings Call2025-02-20
Travere Therapeutics, Inc. (TVTX)
-
Travere Therapeutics, Inc. Q3 FY2024 Earnings Call2024-10-31
Travere Therapeutics, Inc. (TVTX)
-
Travere Therapeutics, Inc. Q2 FY2024 Earnings Call2024-08-01
Travere Therapeutics, Inc. (TVTX)
-
Travere Therapeutics, Inc. Q1 FY2024 Earnings Call2024-05-06
Travere Therapeutics, Inc. (TVTX)
-
Travere Therapeutics, Inc. Q4 FY2023 Earnings Call2024-02-15
Travere Therapeutics, Inc. (TVTX)
-
Travere Therapeutics, Inc. Q3 FY2023 Earnings Call2023-11-07
Travere Therapeutics, Inc. (TVTX)
-
Travere Therapeutics, Inc. Q2 FY2023 Earnings Call2023-08-03
Travere Therapeutics, Inc. (TVTX)
-
Travere Therapeutics, Inc. Q4 FY2022 Earnings Call2023-01-09
Travere Therapeutics, Inc. (TVTX)
-
Travere Therapeutics, Inc. Q3 FY2022 Earnings Call2022-10-27
Travere Therapeutics, Inc. (TVTX)
-
Travere Therapeutics, Inc. Q2 FY2022 Earnings Call2022-08-04
Travere Therapeutics, Inc. (TVTX)
-
Travere Therapeutics, Inc. Q1 FY2022 Earnings Call2022-05-05
Travere Therapeutics, Inc. (TVTX)
-
Travere Therapeutics, Inc. Q3 FY2021 Earnings Call2021-10-28
Travere Therapeutics, Inc. (TVTX)
-
Travere Therapeutics, Inc. Q1 FY2020 Earnings Call2020-05-11
Travere Therapeutics, Inc. (TVTX)